| 000 | 01700 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517123659.0 | ||
| 264 | 0 | _c20180221 | |
| 008 | 201802s 0 0 eng d | ||
| 022 | _a1949-2553 | ||
| 024 | 7 |
_a10.18632/oncotarget.13070 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aXue, Wei | |
| 245 | 0 | 0 |
_aSCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors. _h[electronic resource] |
| 260 |
_bOncotarget _cDec 2016 |
||
| 300 |
_a83088-83100 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xpharmacology |
| 650 | 0 | 4 |
_aCancer Vaccines _ximmunology |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aCytotoxicity, Immunologic _xdrug effects |
| 650 | 0 | 4 |
_aHLA-DR4 Antigen _xgenetics |
| 650 | 0 | 4 |
_aLymphocyte Activation _xdrug effects |
| 650 | 0 | 4 |
_aLymphocytes, Tumor-Infiltrating _xdrug effects |
| 650 | 0 | 4 |
_aMelanoma, Experimental _ximmunology |
| 650 | 0 | 4 | _aMice, Transgenic |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aSkin Neoplasms _ximmunology |
| 650 | 0 | 4 |
_aT-Lymphocytes _xdrug effects |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTumor Microenvironment |
| 650 | 0 | 4 |
_aVaccines, DNA _ximmunology |
| 700 | 1 | _aBrentville, Victoria A | |
| 700 | 1 | _aSymonds, Peter | |
| 700 | 1 | _aCook, Katherine W | |
| 700 | 1 | _aYagita, Hideo | |
| 700 | 1 | _aMetheringham, Rachael L | |
| 700 | 1 | _aDurrant, Lindy G | |
| 773 | 0 |
_tOncotarget _gvol. 7 _gno. 50 _gp. 83088-83100 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.18632/oncotarget.13070 _zAvailable from publisher's website |
| 999 |
_c26587344 _d26587344 |
||